Document Detail

Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals.
MedLine Citation:
PMID:  16601579     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Lower-body negative pressure (LBNP) induces a progressive activation of neurohormonal systems and a renal tubular and haemodynamic response that mimics the renal adaptation observed in congestive heart failure. Both angiotensin II receptor blockers and beta-blockers have been shown to reduce morbidity and mortality in patients with congestive heart failure.
OBJECTIVE: To investigate whether part of the beneficial effects of angiotensin II receptor blockers and beta-blockers in congestive heart failure is mediated through an improvement in renal haemodynamics and sodium excretory capacity.
METHODS AND RESULTS: The study was performed in healthy normotensive individuals exposed to three levels of LBNP and treated with placebo, 200 mg metoprolol once daily, or 16 mg candesartan once daily, for 10 days. Our results show that candesartan increased renal blood flow, and thereby blunted the vasoconstriction induced by LBNP. This effect was not found with metoprolol. More importantly, both metoprolol and candesartan prevented the sodium retention induced by LBNP, but only candesartan promoted sodium excretion during the 2-h recovery period--that is, once LBNP was interrupted.
CONCLUSIONS: These results suggest that blockade of the renin-angiotensin and sympathetic nervous systems in heart failure may be beneficial in part as a result of improved sodium excretion.
Grégoire Wuerzner; Michel Burnier
Related Documents :
15789599 - A dynamic renal phantom for nuclear medicine studies.
10048499 - Hypertensive vascular crisis secondary to chronic total renal artery occlusion.
2534409 - Correlates of atrial natriuretic factor in chronic renal failure.
6366289 - The role of antihypertensive polar renomedullary lipid in the pathogenesis of hypertens...
17442229 - Does remission of renal disease associated with antihypertensive treatment exist?
1343279 - Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients w...
1011079 - Responses of abdominal vascular capacitance in the anaesthetized dog to changes in caro...
22617279 - Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hyper...
11171289 - Cardiovascular regulation during head-up tilt in healthy 20-30-year-old and 70-75-year-...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  24     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-04-07     Completed Date:  2006-07-05     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  S89-93     Citation Subset:  IM    
Service de Néphrologie et Consultation d'Hypertension, CHUV, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-1 Receptor Antagonists*
Adrenergic beta-Antagonists / pharmacology*
Angiotensin II Type 1 Receptor Blockers / pharmacology*
Benzimidazoles / pharmacology*
Blood Pressure / drug effects
Heart Failure / drug therapy*,  physiopathology
Kidney / drug effects*,  physiology
Lower Body Negative Pressure*
Metoprolol / pharmacology*
Renal Circulation / drug effects
Sodium / metabolism*
Tetrazoles / pharmacology*
Reg. No./Substance:
0/Adrenergic beta-1 Receptor Antagonists; 0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Tetrazoles; 37350-58-6/Metoprolol; 7440-23-5/Sodium; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diabetes, nephropathy, and the renin system.
Next Document:  Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in m...